Search
Now showing items 91-100 of 116
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis
(2022-06)
Background: Brexpiprazole augmentation is an effective treatment strategy for antidepressant-refractory depression, but its optimal dosage remains unclear.
Aims: To find the optimal dosage of brexpiprazole as augmentation ...
Investigating inflammation in depression in the chronically ill: Theoretical model and perspectives
(2022-07)
Inflammation is a risk factor for chronic physical illnesses. Evidence is building that inflammation is also a risk factor for mental illnesses making inflammation a common mechanism which could explain the high comorbidity ...
Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment
(2021-10)
Background: Clinical trials with putative antidepressants can be difficult to execute as it can take up to 8 weeks before differences emerge between drug and placebo, and long expensive trials often fail. Implementation ...
No Association Between Amygdala Responses to Negative Faces and Depressive Symptoms: Cross-Sectional Data from 28,638 Individuals in the UK Biobank Cohort
(2022-07)
In this Priority Data Letter, we report on the largest study to date to test the association between amygdala reactivity and depressive symptoms based on UK Biobank data. For transparency, we initially set out to investigate ...
Statins in depression: a repurposed medical treatment can provide novel insights in mental health
(2022-08)
Depression has a large burden, but the development of new drugs for its treatment has proved difficult. Progresses in neuroscience have highlighted several physiopathological pathways, notably inflammatory and metabolic ...
Acute neural effects of fluoxetine on emotional regulation in depressed adolescents
(2022-05)
Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal. Little is known however about how current pharmacotherapies act to modulate ...
Fifty years on: Serotonin and depression
(2023-03)
It has been over 50 years since the original serotonin hypothesis was proposed by the British Psychiatrist Alec Coppen. Recently, some authors have questioned the validity of the hypothesis. In this narrative review, we ...
Machine learning prediction will be part of future treatment of depression
(2023-02)
Machine learning (ML) is changing the way that medicine is practiced. While already clinically utilised in diagnostic radiology and outcome prediction in intensive care unit, ML approaches in psychiatry remain nascent. ...
A systematic review to explore the effectiveness of physical health and psychosocial interventions on anxiety, depression and quality of life in people living with blood cancer
(2023-07)
Problem identification
Anxiety and depression are more prevalent in hematological cancer patients who experience unpredictable illness trajectories and aggressive treatments compared to solid tumor patients. Efficacy of ...
Measuring affect dynamics: An empirical framework
(2023-04)
A fast-growing body of evidence from experience sampling studies suggests that affect dynamics are associated with well-being and health. But heterogeneity in experience sampling approaches impedes reproducibility and ...